DiaMedica Files 20-F Registration Statement with U.S. SEC and Provides Clinical Update

Minneapolis, Minnesota - DiaMedica (TSX VENTURE:DMA) announced that it has filed
a Registration Statement on Form 20-F to register its common shares with the
United States Securities and Exchange Commission (the "SEC"). The filing is
subject to review by the SEC.


"The registration of our common shares with the SEC is an important step in the
process to be listed on a U.S. securities exchange," said Rick Pauls, President
& CEO of DiaMedica. "Listing on a national U.S. stock exchange will enhance our
exposure to the large U.S. biotech investment community."


DiaMedica's registration filing with the SEC follows successful completion of
its Phase 1 program for DM199, which included 50 healthy volunteers. The Phase 1
program clearly demonstrated the safety and tolerability of DM199 along with
supporting the potential for weekly dosing. Subsequently, in a single ascending
dose study in Type 2 diabetic patients, DM199 showed a positive trend towards
improved insulin sensitivity compared to placebo patients as measured by
HOMA2-IR. HOMA2-IR is a measurement of insulin resistance, a primary component
of Type 2 diabetes reflecting the body's inability to effectively process
glucose leading to hyperglycemia (high blood glucose). Specifically, over the
8-day period, HOMA2-IR levels improved or stabilized in the 7 DM199 treated
patients and worsened in the 3 placebo treated patients suggesting a potential
insulin sensitization effect. DM199 is currently being evaluated in a Phase 2
clinical trial in 36 Type 2 diabetic patients who are sequestered over a
one-month treatment period. Results from the Phase 2 study are expected in 2014.


A Form 20-F, once declared effective by the SEC, allows certain foreign issuers
to register securities with the SEC pursuant to applicable U.S. securities laws.



About DiaMedica 

DiaMedica Inc. is a publicly traded (TSX VENTURE:DMA) clinical stage
biopharmaceutical company focused on the discovery and development of novel
therapies to treat diabetes and the complications associated with diabetes.
DiaMedica's lead clinical stage compound, DM199, is a recombinant human protein
known as rhKLK1 that represents a novel approach to treating diabetes and
associated complications. DiaMedica is also developing a novel monoclonal
antibody, DM204 for the treatment of Type 2 diabetes, which is in preclinical
development. 


The Company is listed on the TSX Venture Exchange in Canada under the trading
symbol 'DMA'.


FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Corporation's filings with Canadian securities regulatory authorities. Should
one or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Corporation undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.


FOR FURTHER INFORMATION PLEASE CONTACT: 
DiaMedica Inc.
Rick Pauls
Chairman & CEO
763-710-4455
info@diamedica.com

DiaMedica Inc. (TSXV:DMA)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024